Efficacy and safety of galcanezumab for migraine: evidences from direct and indirect comparisons

References

• MacGregor EA. Migraine. Ann Intern Med. 2017;166(7):ITC49–64.
   PubMedGoogle Scholar
• Gaul C, Finken J, Biermann J, et al. Treatment costs and indirect costs of cluster headache: a health economics analysis. Cephalalgia. 2011;31(16):1664–1672.
   PubMed Web of Science ®Google Scholar
• Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a Web-Based survey. Headache. 2016;56(2):306–322.
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Rastenytė D, Mickevičienė D, Stovner LJ, et al. Prevalence and burden of headache disorders in Lithuania and their public-health and policy implications: a population-based study within the eurolight project. J Headache Pain. 2017;18(1):53–62.
   PubMedGoogle Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, et al. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25–41.
   PubMed Web of Science ®Google Scholar
• Ford JH, Jackson J, Milligan G, et al. A Real-World analysis of migraine: a Cross-Sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532–1544.
   PubMed Web of Science ®Google Scholar
• Galcanezumab. LiverTox: Clinical and research information on Drug-Induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases 2012.
   Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–238.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–187.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Gklinos P, Mitsikostas DD. Galcanezumab in migraine prevention: a systematic review and Meta-analysis of randomized controlled trials. Ther Adv Neurol Disord. 2020;13:1756286420918088.
   Web of Science ®Google Scholar
• Ren Z, Zhang H, Wang R, et al. The treatment efficacy of galcanezumab for migraine: a Meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2019;186:105428–105433.
   PubMed Web of Science ®Google Scholar
• Jen D, Kevin H. Lilly’s Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults. [cited 2018 Sep 27]. Available from https://www.multivu.com/players/English/8386051-lilly-emgality-fda-approval-migraine-treatment/.
   Google Scholar
• Wang X, Chen Y, Song J, et al. Efficacy and safety of monoclonal antibody against calcitonin Gene-Related peptide or its receptor for migraine: a systematic review and network Meta-analysis. Front Pharmacol. 2021;12:649143.
   PubMedGoogle Scholar
• Zhao X, Xu X, Li Q. Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and Meta-analysis. J Neurol. 2021;268(7):2364–2376.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Z, Gao B, et al. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a Meta-analysis of randomized controlled trials. J Headache Pain. 2020;21(1):14–26.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network Meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Headache The international classification of headache disorders. Cephalalgia. 2013;33(9):629–808. 3rd edition (beta version).
   PubMed Web of Science ®Google Scholar
• das Nair R, Martin K-J, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev. 2016;3(3):Cd008754.
   PubMedGoogle Scholar
• Atkins D, Best D, Briss PA, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e21.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188–199.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings ELH, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Neurology. 2014;13(9):885–892.
   PubMed Web of Science ®Google Scholar
• Eli L. A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine. [cited 2020 Feb 21]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02959177.
   Google Scholar
• Mulleners WM, Kim B-K, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–825.
   PubMed Web of Science ®Google Scholar
• Vernieri F, Altamura C, Brunelli N, GARLIT Study Group, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22(1):35.
   PubMed Web of Science ®Google Scholar
• Olesen J. International classification of headache disorders. Lancet Neurol. 2018;17(5):396–397.
   PubMed Web of Science ®Google Scholar
• Manzoni GC, Torelli P. Chronic headaches: a clinician’s experience of ICHD-3 beta. Neurol Sci. 2015;36 Suppl 1(Suppl 1):51–55.
   PubMedGoogle Scholar
• Oakes TMM, Skljarevski V, Zhang Q, et al. Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2b study. Cephalalgia. 2018;38(6):1015–1025.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6–38.
   PubMed Web of Science ®Google Scholar
• Olesen J. The international classification of headache disorders. 2nd edition (ICHD-II). Rev Neurol. 2005;161(6-7):689–691.
   PubMedGoogle Scholar